Poland is among top 20 countries for investment in life sciences, like biotechnology, genetics and pharmaceutical chemistry, according to a report by a global real estate and investment company.
Biotechnology companies quoted on the Warsaw Stock Exchange have seen their valuation increase most among all listed companies during the coronavirus pandemic, a report by accountancy firm Grant Thornton has found.
Launched on June 10, the Warsaw Health Innovation Hub (WHIH) will bring together leading global medical, pharmaceutical and biotechnology companies with the public sector as a first step towards the creation of a Polish Medical Valley inspired by and modelled on medical clusters in other parts of Europe.
The interactive playground at Warsaw’s Copernicus Science Centre is stimulated by children playing which sets off the bioreactors and directly contributes to air purification.
Co-founder and President of the company, Miron Tokarski said: “Our innovative Direct tests will become an effective tool in the fight against pandemic and controlling its population transmission.”
The drug, made by fractionating the plasma of people who were recovering from Covid-19 or who had it asymptomatically, contains anti-SARS-CoV-2 immunoglobulins that can fight and neutralise the deadly virus.
By unravelling the genetic sequence, the researchers can learn a variety of crucial information about the disease, such as how the virus ‘deceives’ the human body, weakening its immune system.
Despite still being at an early stage, Biotechnology is one of the fastest-growing sectors in Poland. Now, biotech company Bioavlee, is taking its Quantica 500 device to Europe.
A Polish firm develops a super yeast that help clean polluted land and water.
The tool combines software, hardware, and biotechnology to provide antibiogram test results and is adjusted to be used at the clinic or even a private office.
This site uses "cookies". By staying on it, you agree to the use of cookies.
